How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Pharma and Healthcare · Forecast 2027–2033
Pulmonary Drugs Market
- By Drug Class: Bronchodilators, Corticosteroids, Leukotriene Modifiers, Mast Cell Stabilizers, Anticholinergics
- By Indication: Asthma, Chronic Obstructive Pulmonary Disease (COPD), Pulmonary Arterial Hypertension, Cystic Fibrosis, Interstitial Lung Disease
- By Route of Administration: Inhalation, Oral, Injectable, Nasal
- By End User: Hospitals, Clinics, Homecare Settings, Specialty Pulmonary Centers
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Projected to reach $X,XXX.XM by 2033 on sustained demand. Market Outlook →
- 03 Growth - X.XX% CAGR across 2027–2033, with the full year-by-year model inside. Market Outlook →
- 04 Leading segment - Bronchodilators leads By Drug Class at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 15 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
11 chapters · 277 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.63 →
- 10 Competitive Landscape 5 sections p.166 →
- 11 Company Profiles 15 players: SWOT & benchmarking p.174 →
Full report · locked preview
Everything inside the Pulmonary Drugs Market report
A complete, evidence-based study - 11 chapters and 116 sections covering market size, segmentation across 4 axes, regional analysis and 15 company profiles, forecast to 2033.
Segmentation covered
Drug Class 5
Indication 5
Route of Administration 4
End User 4
Companies profiled
GlaxoSmithKline plc
AstraZeneca plc
Boehringer Ingelheim GmbH
Novartis International AG
Teva Pharmaceutical Industries Ltd.
Mylan N.V.
Chiesi Farmaceutici S.p.A.
Sun Pharmaceutical Industries Ltd.
Pfizer Inc.
Sanofi S.A.
Bayer AG
Cipla Limited
+3 more
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
15 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →GlaxoSmithKline plc
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →AstraZeneca plc
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Boehringer Ingelheim GmbH
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →Novartis International AG
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →Teva Pharmaceutical Industries Ltd.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →Mylan N.V.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →Chiesi Farmaceutici S.p.A.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.191 →Sun Pharmaceutical Industries Ltd.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →Pfizer Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →Sanofi S.A.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →Bayer AG
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →Cipla Limited
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.220 →Mitsubishi Tanabe Pharma Corporation
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.227 →Hikma Pharmaceuticals PLC
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.232 →Lupin Limited
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.238 →
Global · 2025–2033
$8,565M by 2033 · 8.6% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Bronchodilators31.3
- Corticosteroids16.1
- Leukotriene Modifiers22.3
- Mast Cell Stabilizers16.7
- Anticholinergics13.6
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$1,466M → $2,843M · 8.6%
Europe$1,021M → $2,190M · 10.0%
Asia Pacific$932.7M → $1,847M · 8.9%
Latin America$577.4M → $1,105M · 8.4%
Middle East and Africa$444.1M → $926.1M · 9.6%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →8.512026
8.522027
8.542028
8.532029
8.552030
8.572031
8.592032
8.592033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- GlaxoSmithKline plc15.1
- AstraZeneca plc24.8
- Boehringer Ingelheim GmbH5.0
- Novartis International AG10.8
- Teva Pharmaceutical Industries Ltd.7.2
- Mylan N.V.9.0
- Others28.1
Segment contribution to growth (%)
Fig. 18 · p.39 →Drug Class22.8%
Indication13.1%
Route of Administration36.3%
End User27.8%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America31.9
- Europe24.6
- Asia Pacific20.7
- Latin America12.4
- Middle East and Africa10.4
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| GlaxoSmithKline plc | 81 | 88 | 92 | 84 | 77 | 84 | 84 |
| AstraZeneca plc | 89 | 91 | 90 | 72 | 71 | 68 | 80 |
| Boehringer Ingelheim GmbH | 85 | 76 | 83 | 64 | 81 | 84 | 79 |
| Novartis International AG | 75 | 61 | 65 | 72 | 79 | 75 | 71 |
| Teva Pharmaceutical Industries Ltd. | 62 | 51 | 59 | 54 | 63 | 75 | 61 |
| Mylan N.V. | 71 | 52 | 61 | 58 | 47 | 54 | 57 |
| Chiesi Farmaceutici S.p.A. | 60 | 41 | 50 | 40 | 45 | 56 | 49 |
| Sun Pharmaceutical Industries Ltd. | 46 | 42 | 51 | 57 | 44 | 38 | 46 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- GlaxoSmithKline plc
- AstraZeneca plc
- Boehringer Ingelheim GmbH
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| GlaxoSmithKline plc | ◐ | ✓ | ✓ | ✓ | ◐ | ◐ |
| AstraZeneca plc | ◐ | ◐ | ◐ | ◐ | − | ◐ |
| Boehringer Ingelheim GmbH | ✓ | ◐ | ✓ | − | ✓ | ✓ |
| Novartis International AG | ✓ | − | ◐ | − | ◐ | ◐ |
| Teva Pharmaceutical Industries Ltd. | ◐ | − | − | − | − | ✓ |
| Mylan N.V. | ✓ | − | − | ◐ | ◐ | ◐ |
| Chiesi Farmaceutici S.p.A. | ◐ | − | − | − | − | − |
| Sun Pharmaceutical Industries Ltd. | ◐ | − | ◐ | − | − | − |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1GlaxoSmithKline plc84
2AstraZeneca plc80
3Boehringer Ingelheim GmbH79
4Novartis International AG71
5Teva Pharmaceutical Industries Ltd.61
6Mylan N.V.57
7Chiesi Farmaceutici S.p.A.49
8Sun Pharmaceutical Industries Ltd.46
Competitive tiers
§8.4 · p.172 →Leader3
Set the pace on share, breadth and innovation.
GlaxoSmithKline plcAstraZeneca plcBoehringer Ingelheim GmbH
Challenger1
Strong scale, closing on the leaders.
Novartis International AG
Contender2
Focused players with pockets of strength.
Teva Pharmaceutical Industries Ltd.Mylan N.V.
Niche2
Specialists in a single segment or region.
Chiesi Farmaceutici S.p.A.Sun Pharmaceutical Industries Ltd.
Go-to-market strategy
Land Drug Class in North America, then scale across Pulmonary Drugs Market — a $590M beachhead inside a $9.01B market.
Beachhead (SOM)$590Mobtainable near-term
Serviceable (SAM)$3.23Breachable market
Primary motionPartner-led + digitalgo-to-market
Time to scale6 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion90 fit
Bronchodilators
Best fit — highest urgency & budget in Drug Class.
Economic buyer77 fit
Corticosteroids
Strong fit — clear ROI and a fast path to value.
End user66 fit
Leukotriene Modifiers
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Drug Class in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Indication & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + Route of Administration
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales45%
Partner / channel29%
Digital / self-serve18%
Marketplaces9%
Positioning & messaging
§GTM 2 · p.194 →For Drug Class leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Pulmonary Drugs Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified42%
Sales qualified20%
Evaluation12%
Closed-won7%
$8.3KCAC
$35KLTV
4.2:1LTV : CAC
< 3 moCAC payback
Investment thesis
Pulmonary Drugs Market is a resilient opportunity — $4.08B by 2033, compounding at 3.9%.
TAM · 2025$3.01Btoday
TAM · 2033$4.08Bforecast
CAGR3.9%2027–2033
Cumulative$31.7Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$4.08BTotal addressable market
SAM$1.58BServiceable available market
SOM$266MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →3.9% CAGR
Demand compounds through 2033, outpacing GDP across Drug Class.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Drug Class moving from early to mainstream — durable secular demand.
Consolidation upside
15+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$4.08BLarge & growingTAM by 2033 at 3.9% CAGR
$1.58BServiceable nowreachable with today’s model
$266MBeachhead winobtainable near-term share
15+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$3.18BBear2.5% CAGR
$4.08BBase3.9% CAGR
$5.22BBull5.1% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Indication optionality
- Customer concentrationBroaden installed base beyond top accounts
Board pack · executive summary
Pulmonary Drugs Market — a $4.31B market by 2033. Plan: grow share from 6.8% to 14.9%.
Market size · 2033$4.31Btotal addressable
Market CAGR4.8%2027–2033
Target share14.9%from 6.8% today
Revenue ambition$642Mby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 6.8% | 14.9% | At risk |
| Revenue | $303M | $642M | Behind |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | At risk |
| Segment coverage | 2 of 4 axes | 4 of 4 axes | Ahead |
| Gross margin | 36.7% | 41.3% | On track |
| Customer retention | 88.1% | 92.9% | At risk |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Drug Class
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build Indication capability
A defensible second engine — invest in Indication to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Drug Class share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Indication
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $75M capacity & capability investment
- Greenlight bolt-on M&A in Indication
- Authorise North America expansion plan
- Fund R&D program for Drug Class leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownAt risk
- Competitive share lossOn track
- Input-cost & supply riskAhead
- Regulatory / policy changeAhead
- Execution & talentAt risk
Sales deck · value proposition
Win the Pulmonary Drugs Market conversation — a $3.35B market you can size, segment and defend in minutes.
Market size · 2033$3.35Btotal opportunity
Growth7.2%CAGR to 2033
Addressable buyers1,762+accounts in scope
Typical ROI4.4×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Drug Class
Goal Grow share in Drug Class
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →4.4×return on cost, year one
< 3 mopayback period
$79K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
15+players profiled in this market
Coverage includes
GlaxoSmithKline plcAstraZeneca plcBoehringer Ingelheim GmbHNovartis International AGTeva Pharmaceutical Industries Ltd.Mylan N.V.Chiesi Farmaceutici S.p.A.Sun Pharmaceutical Industries Ltd.+7 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Pulmonary Drugs Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Pulmonary Drugs Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Pharma and Healthcare · scroll →Nuclear Medicine Equipments Market
Market size, share, segmentation and regional forecast.
$12.6B by 2032 · 10.35% CAGR
View reportLiposome Drug Delivery Market
Market size, share, segmentation and regional forecast.
$7.1B by 2033 · 4.36% CAGR
View reportObstructive Sleep Apnea Therapeutic Device Market
Market size, share, segmentation and regional forecast.
$2.0B by 2031 · 10.63% CAGR
View reportOral Vaccine Market
Market size, share, segmentation and regional forecast.
$14.4B by 2031 · 9.14% CAGR
View reportPolypectomy Snare Market
Market size, share, segmentation and regional forecast.
$9.1B by 2032 · 8.17% CAGR
View reportCoextruded Medical Tube Market
Market size, share, segmentation and regional forecast.
$9.6B by 2033 · 8.60% CAGR
View reportCoronary Guidewire Market
Market size, share, segmentation and regional forecast.
$672M by 2033 · 6.05% CAGR
View reportLight Sources For Endoscope Market
Market size, share, segmentation and regional forecast.
$14.3B by 2033 · 8.79% CAGR
View reportOphthalmic Diagnostic Device Market
Market size, share, segmentation and regional forecast.
$12.2B by 2031 · 4.49% CAGR
View reportOphthalmic Operating Microscope Market
Market size, share, segmentation and regional forecast.
$2.1B by 2031 · 5.80% CAGR
View reportOphthalmic Ultrasound Device Market
Market size, share, segmentation and regional forecast.
$12.6B by 2032 · 3.34% CAGR
View reportOphthalmic Viscoelastic Devices (OVDs) Market
Market size, share, segmentation and regional forecast.
$619M by 2032 · 3.23% CAGR
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report ships as a formatted PDF, a fully editable XLSX containing all underlying data tables, and a presentation-ready PPT deck - so you can re-chart, re-model, or drop any figure straight into your own deck.